Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

Psoriatic Arthritis

Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors

Adv Ther

Mease PJ, Ferrante SA, Shiff NJ, Fitzgerald TP, Chakravarty SD, Walsh JA

doi: 10.1007/s12325-024-03042-1

Psoriatic Arthritis

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

Ann Rheum Dis

Karmacharya P, Crofford LJ, Byrne DW, Stephens-Shields A, Husni ME, Scher JU, Craig E, Fitzsimmons R, Reddy SM, Magrey MN, Walsh JA, Ogdie A

doi: 10.1136/ard-2024-226150

Further Publications Rheumatology

Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib

Rheumatology (Oxford)

Hernández-Hernández MV, García-Dorta A, Rodríguez-Regalado C, Hernández-Martín A, Naveda-González E, Martínez-González C, Peña-Montelongo S, Rodríguez Lozano C, González-Dávila E, Díaz-González F

doi: 10.1093/rheumatology/keaf547

Rheumatoid Arthritis

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Arthritis Res Ther

Östör A, Feist E, Sidiropoulos P, Avouac J, Rebella M, Namas R, McDearmon-Blondell E, Gao T, Lagunes-Galindo I, Strengholt S, Zisman D, Attar S

doi: 10.1186/s13075-025-03528-5

PsoriasisPsoriatic ArthritisFurther Publications Rheumatology

Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023

Adv Ther

Puig L, Sewerin P, Schuster C, Ng KJ, Papadimitropoulos M, Gadagamma S, Nuñez M, Lampropoulou A

doi: 10.1007/s12325-025-03258-9

Psoriatic Arthritis

Antimicrobial use and serious infections among psoriatic arthritis patients after initiating tumor necrosis factor inhibitors: a nationwide matched cohort study

J Rheumatol

Thrastardottir T, Bjornsson AH, Ogdie A, Hauksdottir A, Kristinsson SY, Gudbjornsson B, Love TJ, ICEBIO

doi: 10.3899/jrheum.2025-0029

Psoriatic Arthritis

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

RMD Open

McInnes IB, Sewerin P, Sharaf M, Efficace M, Lavie F, Zimmermann M, Coates LC

doi: 10.1136/rmdopen-2024-004494

Rheumatoid Arthritis

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex

Arthritis Res Ther

Flouri ID, Repa A, Avgoustidis N, Pitsigavdaki S, Kalogiannaki E, Kalligianni-Sofikiti K, Emmanouilidou E, Marolachaki E, Bertsias G, Sidiropoulos P

doi: 10.1186/s13075-025-03664-y

Rheumatoid Arthritis

Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study

Rheumatology (Oxford)

Yang Z, Alveyn E, Russell M, Bechman K, Coalwood C, Price E, Abhishek A, Norton S, Galloway J

doi: 10.1093/rheumatology/keae717

Related content

Comparison of On-Label Treatment Persistence in Real-World Patients with Psoriatic Arthritis Receiving Guselkumab Versus Subcutaneous Interleukin-17A Inhibitors

Psoriatic arthritis phenotype clusters and their association with treatment response: a real-world longitudinal cohort study from the psoriatic arthritis research consortium

Real-world data on treatment persistence and measures to minimize cardiovascular risk in rheumatic patients using upadacitinib

Achievement of treatment targets and maintenance of response with upadacitinib in patients with moderate-to-severe rheumatoid arthritis in real-world practice: 1-year outcomes from the UPHOLD observational study

Real-World Evidence for Ixekizumab in the Treatment of Psoriasis, Psoriatic Arthritis, and Axial Spondyloarthritis: Systematic Literature Review 2022-2023

Antimicrobial use and serious infections among psoriatic arthritis patients after initiating tumor necrosis factor inhibitors: a nationwide matched cohort study

Sustained response to guselkumab regardless of baseline characteristics in patients with active psoriatic arthritis and inadequate response to TNF inhibitors: results from the phase 3b COSMOS clinical trial

Long-term comparative analysis of secukinumab versus TNFα inhibitors in patients with spondyloarthritis: treatment persistence is differentially affected by disease phenotype, obesity and sex

Association of patient- and hospital-level predictors with patterns of initial treatment in patients with Rheumatoid Arthritis: findings from a national cohort study